Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Kamarulzaman (2006)
AIDS Res Hum Retroviruses
S. Yerly, S. Vora, Paolo Rizzardi, J. Chave, P. Vernazza, M. Flepp, A. Telenti, M. Battegay, A. Veuthey, J. Bru, M. Rickenbach, Bernard Hirschel, L. Perrin (2001)
Acute HIV infection: impact on the spread of HIV and transmission of drug resistanceAIDS, 15
M. Harris, D. Serwadda, N. Sewankambo, Bohye Kim, G. Kigozi, N. Kiwanuka, James Phillips, Fred Wabwire, Mary Meehen, T. Lutalo, J. Lane, R. Merling, R. Gray, M. Wawer, D. Birx, M. Robb, F. McCutchan (2002)
Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate.AIDS research and human retroviruses, 18 17
Saman Zamani, M. Kihara, M. Gouya, M. Vazirian, Bijan Nassirimanesh, M. Ono‐Kihara, S. Ravari, A. Safaie, S. Ichikawa (2006)
High Prevalence of HIV Infection Associated With Incarceration Among Community-Based Injecting Drug Users in Tehran, IranJAIDS Journal of Acquired Immune Deficiency Syndromes, 42
B. Larijani, F. Zahedi, H. Malekafzali (2005)
Medical ethics in the Islamic Republic of Iran.Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 11 5-6
EM Razzaghi, AR Movaghar (2006)
Profiles of risk: a qualitative study of injecting drug users in Tehran, IranHarm Reduct J, 3
R. Sarrami‐Forooshani, Suman Das, F. Sabahi, A. Adeli, R. Esmaeili, B. Wahren, M. Mohraz, Mahboubeh Haji-Abdolbaghi, M. Rasoolinejad, S. Jameel, F. Mahboudi (2006)
Molecular analysis and phylogenetic characterization of HIV in IranJournal of Medical Virology, 78
S. Duwe, M. Brunn, D. Altmann, O. Hamouda, B. Schmidt, H. Walter, G. Pauli, C. Kücherer (2001)
Frequency of Genotypic and Phenotypic Drug‐Resistant HIV‐1 Among Therapy‐Naive Patients of the German Seroconverter StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 26
H. Naderi, M. Tagliamonte, M. Tornesello, M. Ciccozzi, G. Rezza, Reza Farid, F. Buonaguro, L. Buonaguro (2006)
Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-IranInfectious Agents and Cancer, 1
E. Sanders-Buell, M. Saad, Abdullah Abed, M. Bose, Catherine Todd, S. Strathdee, B. Botros, Naqibullah Safi, K. Earhart, P. Scott, N. Michael, F. McCutchan (2007)
A nascent HIV type 1 epidemic among injecting drug users in Kabul, Afghanistan is dominated by complex AD recombinant strain, CRF35_AD.AIDS research and human retroviruses, 23 6
C. Adje, R. Cheingsong, T. Roels, C. Maurice, G. Djomand, W. Verbiest, K. Hertogs, B. Larder, Ben Monga, M. Peeters, S. Eholie, E. Bissagene, M. Coulibaly, R. Respess, S. Wiktor, T. Chorba, J. Nkengasong (2001)
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.Journal of acquired immune deficiency syndromes, 26 5
A. Altaf, S. Shah, N. Zaidi, A. Memon, Nadeem-ur-Rehman, Norman Wray (2007)
High risk behaviors of injection drug users registered with harm reduction programme in Karachi, PakistanHarm Reduction Journal, 4
M. Tagliamonte, H. Naderi, M. Tornesello, Reza Farid, F. Buonaguro, L. Buonaguro (2007)
HIV type 1 subtype A epidemic in injecting drug user (IDU) communities in Iran.AIDS research and human retroviruses, 23 12
C. Day, Bijan Nassirimanesh, A. Shakeshaft, K. Dolan (2006)
Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in IranHarm Reduction Journal, 3
D. Richman, S. Morton, T. Wrin, N. Hellmann, S. Berry, M. Shapiro, S. Bozzette (2004)
The prevalence of antiretroviral drug resistance in the United StatesAIDS, 18
S. Bertagnolio, L. Soto-Ramírez, R. Pilon, R. Rodríguez, M. Viveros, L. Fuentes, P. Harrigan, T. Mo, D. Sutherland, P. Sandstrom (2007)
HIV-1 drug resistance surveillance using dried whole blood spotsAntiviral Therapy, 12
C. Garrido, N. Zahonero, D. Fernándes, D. Serranò, A. Silva, N. Ferraria, F. Antunes, J. González-Lahoz, V. Soriano, C. Mendoza (2008)
Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola.The Journal of antimicrobial chemotherapy, 61 3
D. Bennett, M. Myatt, S. Bertagnolio, D. Sutherland, C. Gilks (2008)
Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatmentAntiviral Therapy, 13
A. Buckton, Sara Bissett, R. Myers, S. Beddows, S. Edwards, P. Cane, D. Pillay (2008)
Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance.The Journal of antimicrobial chemotherapy, 62 6
M. Vazirian, Bijan Nassirimanesh, Saman Zamani, M. Ono‐Kihara, M. Kihara, Shahrzad Ravari, M. Gouya (2005)
Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: A cross-sectional studyHarm Reduction Journal, 2
Amanda Mcnulty, C. Jennings, D. Bennett, J. Fitzgibbon, J. Bremer, M. Ussery, M. Kalish, W. Heneine, J. García-Lerma (2006)
Evaluation of Dried Blood Spots for Human Immunodeficiency Virus Type 1 Drug Resistance TestingJournal of Clinical Microbiology, 45
M. Kimura (1980)
A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequencesJournal of Molecular Evolution, 16
We performed a pilot surveillance study on transmitted HIV drug resistance (TDR) in Iran, with specimens collected and stored as dried blood spots (DBS). The protease region and relevant positions in the reverse transcriptase region of the pol gene were sequenced to detect mutations known to be associated with resistance to drugs in standard first-line regimens. Seventy-three specimens were collected, with 39 (53%) specimens yielding sequence from both protease and at least part of RT. Specimens were almost exclusively HIV-1 subtype CRF 35_A1D based on pol sequencing. Mutations were restricted to RT, with D67DG and V75AV each seen in a single specimen. An atypical protease inhibitor mutation, I47M, appeared at a resistance-associated position in protease from a single specimen. These preliminary data showed that the rate of transmitted drug resistance in Iran, within the areas sampled, was 5.1% (2/39). However, the small sample size makes this figure only an approximation. Due to the sampling strategy and resulting small sample size, we were unable to accurately calculate TDR rates for individual areas using the WHO HIV drug resistance threshold survey method. Increasing the sample size and improving the yield from DBS would improve the accuracy of drug resistance surveillance and facilitate wider application of this methodology in Iran.
Archives of Virology – Springer Journals
Published: Mar 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.